Citi analyst David Lebowitz maintains $PTC Therapeutics (PTCT.US)$ with a sell rating, and maintains the target price at $26.
According to TipRanks data, the analyst has a success rate of 50.6% and a total average return of 1.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $PTC Therapeutics (PTCT.US)$'s main analysts recently are as follows:
PTC Therapeutics recently disclosed Q2 results, with notable sales for Translarna and Emflaza. However, the future of Translarna in EU markets remains uncertain after several adverse opinions from the Committee for Medicinal Products for Human Use (CHMP). A conclusive CHMP opinion is anticipated by mid-October, which could lead to Translarna's withdrawal from the EU market if unfavorable. The success of the company's pipeline programs is deemed essential before contemplating a change in the current analytical outlook.
Estimations are modestly ahead of the consensus regarding Translarna net product revenues and align with expectations on Emflaza net product revenue. Attention is directed towards gaining insights on the CHMP re-examination process and the provision of further details requested by the FDA concerning the NDA re-submission.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
花旗分析师David Lebowitz维持$PTC Therapeutics (PTCT.US)$卖出评级，维持目标价26美元。
根据TipRanks数据显示，该分析师近一年总胜率为50.6%，总平均回报率为1.3%。
此外，综合报道，$PTC Therapeutics (PTCT.US)$近期主要分析师观点如下：
ptc therapeutics最近披露了第二季度的业绩，Translarna和Emflaza的销售额值得关注。然而，在数次来自CHMP的不利意见后，Translarna在欧盟市场的未来仍然不确定。预计CHMP将在十月中旬做出决定性意见，如果不利的话可能导致Translarna从欧盟市场撤出。在考虑当前的分析前景改变之前，公司管道项目的成功被视为至关重要。
对于Translarna净产品营业收入的预估略高于共识，与Emflaza净产品营业收入的预期一致。注意力集中在获取对CHMP重新审查过程的见解，以及满足FDA关于新药申请重新提交的进一步细节要求。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
